Journal
JOURNAL OF ENDOCRINOLOGY
Volume 221, Issue 1, Pages T1-T16Publisher
BIOSCIENTIFICA LTD
DOI: 10.1530/JOE-13-0414
Keywords
glucagon-like peptide 1; CNS; feeding behaviour; obesity; type 2 diabetes
Categories
Funding
- Abbott
- BMS-Astra
- Boehringer-Ingelheim
- Eli Lilly
- Medtronic
- MSD
- Novo Nordisk
- Sanofi
Ask authors/readers for more resources
The delivery of nutrients to the gastrointestinal tract after food ingestion activates the secretion of several gut-derived mediators, including the incretin hormone glucagon-like peptide 1 (GLP-1). GLP-1 receptor agonists (GLP-1RA), such as exenatide and liraglutide, are currently employed successfully in the treatment of patients with type 2 diabetes mellitus. GLP-1RA improve glycaemic control and stimulate satiety, leading to reductions in food intake and body weight. Besides gastric distension and peripheral vagal nerve activation, GLP-1RA induce satiety by influencing brain regions involved in the regulation of feeding, and several routes of action have been proposed. This review summarises the evidence for a physiological role of GLP-1 in the central regulation of feeding behaviour and the different routes of action involved. Also, we provide an overview of presently available data on pharmacological stimulation of GLP-1 pathways leading to alterations in CNS activity, reductions in food intake and weight loss.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available